Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Clinical Trials in Houston, Texas

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib